Full CoverageRegeneron, playing catch up with J&J and Pfizer, wins FDA approval for Lynozyfic in multiple myeloma
By Angus Liu
All coverage
Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma
By Roman Fabbricatore
Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity
By Tristan Cesar Manalac
Regeneron wins FDA nod for BCMA bispecific Lynozyfic
By Jennifer Boggs
FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma
By Hayden E. Klein
FDA Approves Regeneron Multiple Myeloma Drug With Dosing Edge Over J&J and Pfizer Meds
By Frank Vinluan
US FDA approves Regeneron’s blood cancer therapy
By Shailesh Kuber, Puyaan Singh & Sahal Muhammed
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
By Luke Halpern
Regeneron wins FDA nod for multiple myeloma drug (REGN:NASDAQ)
By Dulan Lokuwithana
US FDA approves Regeneron’s blood cancer therapy
By Scot Facer Proctor
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
By Vandana Singh
US FDA approves Regeneron's blood cancer therapy
By Leroy Leo, Sahal Muhammed & Puyaan Singh